TNF-α: A Benificial or Harmful Pathogenic Cytokine in Cardiovascular System
Tumor necrosis factor (TNF- alpha) plays important role in pathophysiology of cardiovascular system and had been comprehensively studied over the last 20 years. These studies demonstrate both Detrimental and potentially conflicting roles of TNF-α in pathophysiology of heart. Beneficial effects of TNF-α includes cardioprotective action against ischemia, myocarditis, pressure overload and preventive action against potential adverse effects including development of atherosclerosis, reperfusion injury, hypertrophy, and heart failure. However, TNF-α is still controversial for its beneficial or harmful effects for cardiovascular system. This review includes evaluation of possible role of TNF-α in cardiovascular system specifically in pathophysiology and morphology of cardiomyocytes. Further this article mainly emphases on the claimed role of TNF-α pathways with concerning essential cardiac cellular processes which may have unswerving adaptive effects in the heart with respect to future research directions.
Keywords: Tumor Necrosis Factor, Hypertrophy, Pathophysiology, Cytokine, Pathology, Cardiovascular System.
2. Ruddle NH. Lymphotoxin and TNF: how it all began—a tribute to the travelers. Cytokine & growth factor reviews. 2014; 25(2):83-9.
3. Vujanovic NL. Role of TNF superfamily ligands in innate immunity. Immunologic research. 2011; 50(2-3):159-74.
4. Farasat S, Aksentijevich I, Toro JR. Autoinflammatory diseases: clinical and genetic advances. Archives of dermatology. 2008; 144(3):392-402.
5. Kumar S. Apoptosis: biology and mechanisms: Springer Science & Business Media; 2013.
6. Petkova-Kirova PS, Gursoy E, Mehdi H, McTiernan CF, London B, Salama G. Electrical remodeling of cardiac myocytes from mice with heart failure due to the overexpression of tumor necrosis factor-α. American Journal of Physiology-Heart and Circulatory Physiology. 2006; 290(5):H2098-H107.
7. Zhang S, He H, Day AJ, Tseng SC. Constitutive expression of inter-α-inhibitor (IαI) family proteins and tumor necrosis factor-stimulated gene-6 (TSG-6) by human amniotic membrane epithelial and stromal cells supporting formation of the heavy chain-hyaluronan (HC-HA) complex. Journal of biological chemistry. 2012; 287(15):12433-44.
8. Montgomery SL, Bowers WJ. Tumor necrosis factor-alpha and the roles it plays in homeostatic and degenerative processes within the central nervous system. Journal of neuroimmune pharmacology. 2012; 7(1):42-59.
9. Nielsen OH, Ainsworth MA. Tumor necrosis factor inhibitors for inflammatory bowel disease. New England Journal of Medicine. 2013; 369(8):754-62.
10. Chu W-M. Tumor necrosis factor. Cancer letters. 2013; 328(2):222-5.
11. Shabbir A, Batool SA, Basheer MI, Shahzad M, Sultana K, Tareen RB, et al. Ziziphora clinopodioides ameliorated rheumatoid arthritis and inflammatory paw edema in different models of acute and chronic inflammation. Biomedicine & Pharmacotherapy. 2018; 97:1710-21.
12. MYERS MJ, MURTAUGH MP. Biology of Ttomor Necrosis Factor. Cytokines in animal health and disease. 2020.
13. Kao Y-H, Chen Y-C, Cheng C-C, Lee T-I, Chen Y-J, Chen S-A. Tumor necrosis factor-α decreases sarcoplasmic reticulum Ca2+-ATPase expressions via the promoter methylation in cardiomyocytes. Critical care medicine. 2010; 38(1):217-22.
14. Zhang Z, Zhu L, Feng P, Tan Y, Zhang B, Gao E, et al. C1q/tumor necrosis factor-related protein-3-engineered mesenchymal stromal cells attenuate cardiac impairment in mice with myocardial infarction. Cell death & disease. 2019; 10(7):1-15.
15. Cabrera-Fuentes HA, Ruiz-Meana M, Simsekyilmaz S, Kostin S, Inserte J, Saffarzadeh M, et al. RNase1 prevents the damaging interplay between extracellular RNA and tumour necrosis factor-α in cardiac ischaemia/reperfusion injury. Thrombosis & Haemostasis. 2014; 112(6):1110-9.
16. Selvasandran K, Makhoul G, Jaiswal PK, Jurakhan R, Li L, Ridwan K, et al. A tumor necrosis factor-α and hypoxia-induced secretome therapy for myocardial repair. The Annals of thoracic surgery. 2018; 105(3):715-23.
17. Li J, Xie C, Zhuang J, Li H, Yao Y, Shao C, et al. Resveratrol attenuates inflammation in the rat heart subjected to ischemia-reperfusion: Role of the TLR4/NF-κB signaling pathway. Molecular medicine reports. 2015; 11(2):1120-6.
18. King EG, Bauzá GJ, Mella JR, Remick DG. Pathophysiologic mechanisms in septic shock. Laboratory investigation. 2014; 94(1):4-12.
19. Sandek A, Bjarnason I, Volk H-D, Crane R, Meddings JB, Niebauer J, et al. Studies on bacterial endotoxin and intestinal absorption function in patients with chronic heart failure. International journal of cardiology. 2012; 157(1):80-5.
20. Zhou M, Liu L, Wang W, Han J, Ren H, Zheng Q, et al. Role of licochalcone C in cardioprotection against ischemia/reperfusion injury of isolated rat heart via antioxidant, anti-inflammatory, and anti-apoptotic activities. Life sciences. 2015; 132:27-33.
21. Olleros ML, Chavez-Galan L, Segueni N, Bourigault ML, Vesin D, Kruglov AA, et al. Control of mycobacterial infections in mice expressing human tumor necrosis factor (TNF) but not mouse TNF. Infection and Immunity. 2015; 83(9):3612-23.
22. Pena E, Brito J, El Alam S, Siques P. Oxidative Stress, Kinase Activity and Inflammatory Implications in Right Ventricular Hypertrophy and Heart Failure under Hypobaric Hypoxia. International Journal of Molecular Sciences. 2020; 21(17):6421.
23. Burchfield JS, Dong J-W, Sakata Y, Gao F, Tzeng H-P, Topkara VK, et al. The Cytoprotective Effects of Tumor Necrosis Factor Are Conveyed Through Tumor Necrosis Factor Receptor–Associated Factor 2 in the Heart. Circulation: Heart Failure. 2010; 3(1):157-64.
24. Schumacher SM, Prasad SVN. Tumor necrosis factor-α in heart failure: an updated review. Current cardiology reports. 2018; 20(11):117.
25. Yang F-L, Subeq Y-M, Chiu Y-H, Lee R-P, Lee C-J, Hsu B-G. Recombinant human erythropoietin reduces rhabdomyolysis-induced acute renal failure in rats. Injury. 2012; 43(3):367-73.
26. Yin J, Tu C, Zhao J, Ou D, Chen G, Liu Y, et al. Exogenous hydrogen sulfide protects against global cerebral ischemia/reperfusion injury via its anti-oxidative, anti-inflammatory and anti-apoptotic effects in rats. Brain research. 2013;1491:188-96.
27. Zhai J, Guo Y. Paeoniflorin attenuates cardiac dysfunction in endotoxemic mice via the inhibition of nuclear factor-κB. Biomedicine & Pharmacotherapy. 2016; 80:200-6.
28. Kakihana Y, Ito T, Nakahara M, Yamaguchi K, Yasuda T. Sepsis-induced myocardial dysfunction: pathophysiology and management. Journal of intensive care. 2016; 4(1):1-10.
29. Hedayat M, Mahmoudi MJ, Rose NR, Rezaei N. Proinflammatory cytokines in heart failure: double-edged swords. Heart failure reviews. 2010; 15(6):543-62.
30. Du L, Dronadula N, Tanaka S, Dichek DA. Helper-dependent adenoviral vector achieves prolonged, stable expression of interleukin-10 in rabbit carotid arteries but does not limit early atherogenesis. Human gene therapy. 2011; 22(8):959-68.
31. An J, Du J, Wei N, Guan T, Camara AK, Shi Y. Differential sensitivity to LPS-induced myocardial dysfunction in the isolated Brown Norway and Dahl S rat hearts: roles of mitochondrial function, NFκB activation and TNF-α production. Shock (Augusta, Ga). 2012; 37(3):325.
32. Lind M, Hayes A, Caprnda M, Petrovic D, Rodrigo L, Kruzliak P, et al. Inducible nitric oxide synthase: good or bad? Biomedicine & Pharmacotherapy. 2017; 93:370-5.
33. Lee J-Y, Kim JH, Chae G, Lee B-K, Ha K-S, Kwon Y-G, et al. Cyclic AMP prolongs graft survival by suppressing apoptosis and inflammatory gene expression in acute cardiac allograft rejection. Experimental & molecular medicine. 2010; 42(1):69-79.
34. Torzewski M, Wenzel P, Kleinert H, Becker C, El-Masri J, Wiese E, et al. Chronic inflammatory cardiomyopathy of interferon γ–overexpressing transgenic mice Is mediated by tumor necrosis factor-α. The American journal of pathology. 2012; 180(1):73-81.
35. Razazi K, Boissier F, Surenaud M, Bedet A, Seemann A, Carteaux G, et al. A multiplex analysis of sepsis mediators during human septic shock: A preliminary study on myocardial depression and organ failures. Annals of intensive care. 2019; 9(1):64.
36. Zhang Y, Cao Y, Xin L, Gao N, Liu B. Association between rs1800629 polymorphism in tumor necrosis factor-α gene and dilated cardiomyopathy susceptibility: Evidence from case–control studies. Medicine. 2018; 97(50).
37. Hu H, Zhai C, Qian G, Gu A, Liu J, Ying F, et al. Protective effects of tanshinone IIA on myocardial ischemia reperfusion injury by reducing oxidative stress, HMGB1 expression, and inflammatory reaction. Pharmaceutical biology. 2015; 53(12):1752-8.
38. Lecour S, Minners J, Rochette L, Opie L, Sack M, editors. Tumor necrosis factor alpha confers cardiac preconditioning: Possible role of mitochondrial K-ATP channel mediated event. Circulation; 1999: LIPPINCOTT WILLIAMS & WILKINS 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA.
39. Tomé-Carneiro J, Larrosa M, Yáñez-Gascón MJ, Dávalos A, Gil-Zamorano J, Gonzálvez M, et al. One-year supplementation with a grape extract containing resveratrol modulates inflammatory-related microRNAs and cytokines expression in peripheral blood mononuclear cells of type 2 diabetes and hypertensive patients with coronary artery disease. Pharmacological research. 2013; 72:69-82.
40. Hori M, Yamaguchi O. Is tumor necrosis factor-α friend or foe for chronic heart failure? Circulation research. 2013; 113(5):492-4.
41. Askevold ET, Gullestad L, Dahl CP, Yndestad A, Ueland T, Aukrust P. Interleukin-6 signaling, soluble glycoprotein 130, and inflammation in heart failure. Current heart failure reports. 2014; 11(2):146-55.
42. Tschöpe C, Cooper LT, Torre-Amione G, Van Linthout S. Management of myocarditis-related cardiomyopathy in adults. Circulation research. 2019; 124(11):1568-83.
43. Charbonney E, Tsang JY, Li Y, Klein D, Duque P, Romaschin A, et al. Endotoxemia following multiple trauma: risk factors and prognostic implications. Critical Care Medicine. 2016; 44(2):335-41.
44. Putko BN, Wang Z, Lo J, Anderson T, Becher H, Dyck JR, et al. Circulating levels of tumor necrosis factor-alpha receptor 2 are increased in heart failure with preserved ejection fraction relative to heart failure with reduced ejection fraction: evidence for a divergence in pathophysiology. PloS one. 2014; 9(6):e99495.
45. Nagpure B, Bian J-S. Interaction of hydrogen sulfide with nitric oxide in the cardiovascular system. Oxidative medicine and cellular longevity. 2016; 2016.
46. Ghebre YT, Yakubov E, Wong WT, Krishnamurthy P, Sayed N, Sikora AG, et al. Vascular aging: implications for cardiovascular disease and therapy. Translational medicine (Sunnyvale, Calif). 2016; 6(4).
47. Yamagata K, Suzuki S, Tagami M. Docosahexaenoic acid prevented tumor necrosis factor alpha-induced endothelial dysfunction and senescence. Prostaglandins, Leukotrienes and Essential Fatty Acids. 2016; 104:11-8.
48. Yoshizumi M, Perrella MA, Burnett Jr J, Lee M-E. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circulation research. 1993; 73(1):205-9.
49. Liang J, Nagahashi M, Kim EY, Harikumar KB, Yamada A, Huang W-C, et al. Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer. Cancer cell. 2013; 23(1):107-20.
50. Zhang J, Wu G, Dai H. The matricellular protein CCN1 regulates TNF‐α induced vascular endothelial cell apoptosis. Cell biology international. 2016; 40(1):1-6.
51. Li J, Hao J. Treatment of neurodegenerative diseases with bioactive components of Tripterygium wilfordii. The American Journal of Chinese Medicine. 2019; 47(04):769-85.
52. Panth N, Paudel KR, Parajuli K. Reactive oxygen species: a key hallmark of cardiovascular disease. Advances in medicine. 2016; 2016.
53. Carreras A, Zhang SX, Peris E, Qiao Z, Gileles-Hillel A, Li RC, et al. Chronic sleep fragmentation induces endothelial dysfunction and structural vascular changes in mice. Sleep. 2014; 37(11):1817-24.
54. Picchi A, Gao X, Belmadani S, Potter BJ, Focardi M, Chilian WM, et al. Tumor necrosis factor-α induces endothelial dysfunction in the prediabetic metabolic syndrome. Circulation research. 2006;99(1):69-77.
55. Aoki N, Siegfried M, Lefer AM. Anti-EDRF effect of tumor necrosis factor in isolated, perfused cat carotid arteries. American Journal of Physiology-Heart and Circulatory Physiology. 1989; 256(5):H1509-H12.
56. Ahmad M, Zhang Y, Zhang Y, Papharalambus C, Alexander RW. Role of isoprenylcysteine carboxyl methyltransferase in tumor necrosis factor-α stimulation of expression of vascular cell adhesion molecule-1 in endothelial cells. Arteriosclerosis, thrombosis, and vascular biology. 2002; 22(5):759-64.
57. Wu Y, Qin C, Lu X, Marchiori J, Feng Q. North American ginseng inhibits myocardial NOX2-ERK1/2 signaling and tumor necrosis factor-α expression in endotoxemia. Pharmacological research. 2016; 111:217-25.
58. Han J, Zou C, Mei L, Zhang Y, Qian Y, You S, et al. MD2 mediates angiotensin II-induced cardiac inflammation and remodeling via directly binding to Ang II and activating TLR4/NF-κB signaling pathway. Basic research in cardiology. 2017; 112(1):9.
59. Siddesha JM, Valente AJ, Sakamuri SS, Yoshida T, Gardner JD, Somanna N, et al. Angiotensin II stimulates cardiac fibroblast migration via the differential regulation of matrixins and RECK. Journal of molecular and cellular cardiology. 2013; 65:9-18.
60. Zou J, Li H, Chen X, Zeng S, Ye J, Zhou C, et al. C/EBPβ knockdown protects cardiomyocytes from hypertrophy via inhibition of p65-NFκB. Molecular and cellular endocrinology. 2014; 390(1-2):18-25.
61. Tang F, Lu M, Yu L, Wang Q, Mei M, Xu C, et al. Inhibition of TNF-α–mediated NF-κB Activation by Ginsenoside Rg1 Contributes the Attenuation of Cardiac Hypertrophy Induced by Abdominal Aorta Coarctation. Journal of Cardiovascular Pharmacology. 2016; 68(4):257-64.
62. Papathanasiou S, Rickelt S, Soriano ME, Schips TG, Maier HJ, Davos CH, et al. Tumor necrosis factor-α confers cardioprotection through ectopic expression of keratins K8 and K18. Nature medicine. 2015; 21(9):1076.
63. Lubrano V, Balzan S. Consolidated and emerging inflammatory markers in coronary artery disease. World journal of experimental medicine. 2015; 5(1):21.
64. Eskandari V, Amirzargar A, Mahmoudi M, Rahnemoon Z, Rahmani F, Sadati S, et al. Gene expression and levels of IL-6 and TNFα in PBMCs correlate with severity and functional class in patients with chronic heart failure. Irish Journal of Medical Science (1971-). 2018; 187(2):359-68.
65. Gullestad L, Ueland T, Vinge LE, Finsen A, Yndestad A, Aukrust P. Inflammatory cytokines in heart failure: mediators and markers. Cardiology. 2012; 122(1):23-35.
66. Prabhu SD, Frangogiannis NG. The biological basis for cardiac repair after myocardial infarction: from inflammation to fibrosis. Circulation research. 2016; 119(1):91-112.
67. Heusch G. Cardioprotection: chances and challenges of its translation to the clinic. The Lancet. 2013; 381(9861):166-75.
68. Gedik N, Maciel L, Schulte C, Skyschally A, Heusch G, Kleinbongard P. Cardiomyocyte mitochondria as targets of humoral factors released by remote ischemic preconditioning. Archives of medical science: AMS. 2017; 13(2):448.
69. Robertson FP, Fuller BJ, Davidson BR. An evaluation of ischaemic preconditioning as a method of reducing ischaemia reperfusion injury in liver surgery and transplantation. Journal of clinical medicine. 2017; 6(7):69.
70. Thirupathi A, De Souza CT. Multi-regulatory network of ROS: the interconnection of ROS, PGC-1 alpha, and AMPK-SIRT1 during exercise. Journal of physiology and biochemistry. 2017; 73(4):487-94.
71. Chemaly M, McGilligan V, Gibson M, Clauss M, Watterson S, Alexander HD, et al. Role of tumour necrosis factor alpha converting enzyme (TACE/ADAM17) and associated proteins in coronary artery disease and cardiac events. Archives of Cardiovascular Diseases. 2017; 110(12):700-11.
72. Philip J, Xu Z, Bowles NE, Vallejo JG. Cardiac-specific overexpression of melanoma differentiation–associated gene-5 protects mice from lethal viral myocarditis. Circulation: Heart Failure. 2013; 6(2):326-34.
73. Benjamin MM, Khalil RA. Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease. Matrix metalloproteinase inhibitors: Springer; 2012. p. 209-79.
74. Wang D, Li T, Cui H, Zhang Y. Analysis of the indicating value of cardiac troponin i, tumor necrosis factor-α, interleukin-18, Mir-1 and Mir-146b for viral myocarditis among children. Cellular Physiology and Biochemistry. 2016; 40(6):1325-33.
75. Zhang Y, Zhao J, Lau WB, Jiao L-Y, Liu B, Yuan Y, et al. Tumor necrosis factor-α and lymphotoxin-α mediate myocardial ischemic injury via TNF receptor 1, but are cardioprotective when activating TNF receptor 2. PloS one. 2013; 8(5):e60227.
76. Brunham RC, Gottlieb SL, Paavonen J. Pelvic inflammatory disease. New England Journal of Medicine. 2015; 372(21):2039-48.
77. Skjøt-Arkil H, Barascuk N, Larsen L, Dziegiel M, Henriksen K, Karsdal MA. Tumor Necrosis Factor-Alpha and Receptor Activator of Nuclear Factor-κB Ligand Augment Human Macrophage Foam-Cell Destruction of Extracellular Matrix Through Protease-Mediated Processes. ASSAY and Drug Development Technologies. 2012; 10(1):69-77.
78. Zeya B, Arjuman A, Chandra NC. Lectin-like oxidized low-density lipoprotein (LDL) receptor (LOX-1): a chameleon receptor for oxidized LDL. Biochemistry. 2016; 55(32):4437-44.
79. Yang C-Q, Li W, Li S-Q, Li J, Li Y-W, Kong S-X, et al. MCP-1 stimulates MMP-9 expression via ERK 1/2 and p38 MAPK signaling pathways in human aortic smooth muscle cells. Cellular Physiology and Biochemistry. 2014; 34(2):266-76.
80. Bekkering S, Stiekema LC, Moens SB, Verweij SL, Novakovic B, Prange K, et al. Treatment with statins does not revert trained immunity in patients with familial hypercholesterolemia. Cell metabolism. 2019; 30(1):1-2.
81. Umebayashi R, Uchida HA, Okuyama Y, Kakio Y, Hanayama Y, Shikata K, et al. The clinical efficacy of angiotensin II type1 receptor blockers on inflammatory markers in patients with hypertension: a multicenter randomized-controlled trial; MUSCAT-3 study. Biomarkers. 2019; 24(3):255-61
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).